Zegfrovy Sunvozertinib DZD9008 drug, a quite new therapeutic agent, is generating significant interest within the cancer community. Its mechanism of action primarily involves targeted inhibition of epidermal growth factor receptor (EGFR) kinase activity, showing potential in treating various cancerous types. Early clinical studies have demonstrated